Sylvain Rheims1, Sebastià Rubi1, Sandrine Bouvard1, Emilien Bernard1, Nathalie Streichenberger1, Marc Guenot1, Didier Le Bars1, Alexander Hammers1, Philippe Ryvlin1. 1. Department of Functional Neurology and Epileptology and Institute of Epilepsies (IDEE) (S.Rh., E.B., P.R.); Department of Pathology (N.S.); Department of Functional Neurosurgery (M.G.); Hospices Civils de Lyon, Lyon, France; Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR5292, Lyon, France (S.Rh., S.B., P.R.); CERMEP-Imagerie du Vivant, Lyon, France (S.B., D.L.B.); Neurodis Foundation, CERMEP-Imagerie du Vivant, Lyon, France (A.H.); Hospital Clinic de Barcelona, Barcelona, Spain (S.Ru.).
Abstract
BACKGROUND: Dysembryoplastic neuroepithelial tumors (DNTs) represent a prevalent cause of epileptogenic brain tumors, the natural evolution of which is much more benign than that of most gliomas. Previous studies have suggested that [(11)C]methionine positron emission tomography (MET-PET) could help to distinguish DNTs from other epileptogenic brain tumors, and hence optimize the management of patients. Here, we reassessed the diagnostic accuracy of MET-PET for the differentiation between DNT and other epileptogenic brain neoplasms in a larger population. METHODS: We conducted a retrospective study of 77 patients with focal epilepsy related to a nonrapidly progressing brain tumor on MRI who underwent MET-PET, including 52 with a definite histopathology. MET-PET data were assessed by a structured visual analysis that distinguished normal, moderately abnormal, and markedly abnormal tumor methionine uptake and by semiquantitative ratio measurements. RESULTS: Pathology showed 21 DNTs (40%), 10 gangliogliomas (19%), 19 low-grade gliomas (37%), and 2 high-grade gliomas (4%). MET-PET visual findings significantly differed among the various tumor types (P < .001), as confirmed by semiquantitative analyses (P < .001 for all calculated ratios), regardless of gadolinium enhancement on MRI. All gliomas and gangliogliomas were associated with moderately or markedly increased tumor methionine uptake, whereas 9/21 DNTs had normal methionine uptake. Receiver operating characteristics analysis of the semiquantitative ratios showed an optimal cutoff threshold that distinguished DNTs from other tumor types with 90% specificity and 89% sensitivity. CONCLUSIONS: Normal MET-PET findings in patients with an epileptogenic nonrapidly progressing brain tumor are highly suggestive of DNT, whereas a markedly increased tumor methionine uptake makes this diagnosis unlikely.
BACKGROUND:Dysembryoplastic neuroepithelial tumors (DNTs) represent a prevalent cause of epileptogenic brain tumors, the natural evolution of which is much more benign than that of most gliomas. Previous studies have suggested that [(11)C]methionine positron emission tomography (MET-PET) could help to distinguish DNTs from other epileptogenic brain tumors, and hence optimize the management of patients. Here, we reassessed the diagnostic accuracy of MET-PET for the differentiation between DNT and other epileptogenic brain neoplasms in a larger population. METHODS: We conducted a retrospective study of 77 patients with focal epilepsy related to a nonrapidly progressing brain tumor on MRI who underwent MET-PET, including 52 with a definite histopathology. MET-PET data were assessed by a structured visual analysis that distinguished normal, moderately abnormal, and markedly abnormal tumormethionine uptake and by semiquantitative ratio measurements. RESULTS: Pathology showed 21 DNTs (40%), 10 gangliogliomas (19%), 19 low-grade gliomas (37%), and 2 high-grade gliomas (4%). MET-PET visual findings significantly differed among the various tumor types (P < .001), as confirmed by semiquantitative analyses (P < .001 for all calculated ratios), regardless of gadolinium enhancement on MRI. All gliomas and gangliogliomas were associated with moderately or markedly increased tumormethionine uptake, whereas 9/21 DNTs had normal methionine uptake. Receiver operating characteristics analysis of the semiquantitative ratios showed an optimal cutoff threshold that distinguished DNTs from other tumor types with 90% specificity and 89% sensitivity. CONCLUSIONS: Normal MET-PET findings in patients with an epileptogenic nonrapidly progressing brain tumor are highly suggestive of DNT, whereas a markedly increased tumormethionine uptake makes this diagnosis unlikely.
Authors: Burkhard S Kasper; Tobias Struffert; Ekkehard M Kasper; Torsten Fritscher; Elisabeth Pauli; Daniel Weigel; Frank Kerling; Thilo Hammen; Wolfgang Graf; Torsten Kuwert; Olaf Prante; Bogdan Lorber; Michael Buchfelder; Arnd Doerfler; Stefan Schwab; Hermann Stefan; Rainer Linke Journal: Epilepsia Date: 2010-10-13 Impact factor: 5.864
Authors: O De Witte; I Goldberg; D Wikler; S Rorive; P Damhaut; M Monclus; I Salmon; J Brotchi; S Goldman Journal: J Neurosurg Date: 2001-11 Impact factor: 5.115
Authors: Wilson Z Ray; Spiros L Blackburn; Sandro Casavilca-Zambrano; Carlos Barrionuevo; Jose E Orrego; Hugo Heinicke; Joshua L Dowling; Arie Perry Journal: J Neurooncol Date: 2009-03-08 Impact factor: 4.130
Authors: Georges Sinclair; Heather Martin; Alia Shamikh; Amir Samadi; Gerald Cooray; Jiri Bartek; Yehya Al-Saffar; Mikael Svensson; Ernest Dodoo Journal: Surg Neurol Int Date: 2017-08-09